{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:09:23Z","timestamp":1784268563999,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Although most cases of estrogen receptor-positive (ER+) breast cancer initially respond to endocrine therapy, many patients ultimately develop resistance. A major contributor to endocrine resistance in metastatic disease is the acquisition of constitutively active somatic mutations in the estrogen receptor ligand-binding domain (LBD). We previously identified midasin (MDN1), a ribosome biogenesis protein, as significantly overexpressed in letrozole-resistant MCF-7 cells. Because these cells are ER\n                      <jats:sup>low\/\u2212<\/jats:sup>\n                      and represent only a subset of endocrine-resistant tumors, we hypothesized that ESR1 mutations cooperate with MDN1 dysregulation to confer a survival advantage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address this, the cBioPortal database was queried to assess correlations between breast cancer subtypes and MDN1 expression levels. MCF-7 cell lines harboring ER point mutations were evaluated by RNA sequencing and immunoblot analysis to measure ER and MDN1 expression. To identify pharmacologic inhibitors of midasin, computational docking analyses were performed using a panel of ribozinoindole (Rbin) analogs, followed by biological evaluation studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Initial analyses demonstrated that MDN1 expression is elevated in human breast cancer tumors, including luminal, HER2+, and triple-negative breast cancer. RNA sequencing of parental MCF-7 cells and ESR1-mutant derivatives, MCF-7 Y537S and MCF-7 D538G, revealed comparable MDN1 transcript levels across all cell lines. In contrast, immunoblot analysis showed mutation-dependent differences in MDN1 protein expression, with the highest levels observed in MCF-7 D538G cells, followed by MCF-7 Y537S cells and then parental MCF-7 cells. Computational docking analyses of Rbin analogs led to the selection of Rbin-1 and Rbin-2 for biological evaluation. Viability assays revealed minimal activity for Rbin-1, whereas Rbin-2 reduced proliferation by 30%\u201355% across all three cell lines, with the most pronounced effects observed in MCF-7 D538G cells at 24 and 48 h. Consistent with these findings, Rbin-2 treatment decreased MDN1 protein expression by approximately 50% in all cell lines, while ER levels remained largely unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Collectively, these results establish the feasibility of pharmacologically targeting midasin in mammalian cell lines and support a functional link between MDN1 expression and ESR1 mutation-driven endocrine resistance. This work provides a foundation for future mechanistic studies of midasin as a potential therapeutic vulnerability in ER-mutant breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1852788","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:42:46Z","timestamp":1784266966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Mounika","family":"Pamukuntla","sequence":"first","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afia","family":"Ohemeng","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipika","family":"Banjara","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Kotina","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, College of Science and Technology","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simak","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London Hammersmith Hospital Campus","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Darling-Reed","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Burow","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Tulane Department of Medicine, Tulane University Health Science Center","place":["New Orleans, LA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Gangapuram","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Eyunni","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaylen","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Hilliard","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Davidson","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Henderson","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hampton University","place":["Hampton, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syreeta L.","family":"Tilghman","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University","place":["Tallahassee, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13058-017-0851-4","article-title":"Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models","volume":"19","author":"Bahreini","year":"2017","journal-title":"Breast Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1538-7445.am2025-15","article-title":"Abstract 15: Midasin is required for mammosphere stability in letrozole resistant breast cancer","volume":"85","author":"Banjara","year":"2025","journal-title":"Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cell.2018.09.015","article-title":"Structural insights into Mdn1, an essential AAA protein required for ribosome biogenesis","volume":"175","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e81843","DOI":"10.1371\/journal.pone.0081843","article-title":"Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling","volume":"9","author":"Cornen","year":"2014","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev.biophys.35.040405.101933","article-title":"Evolutionary relationships and structural mechanisms of AAA+ proteins","volume":"35","author":"Erzberger","year":"2006","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"Elife"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"540134","DOI":"10.3389\/fonc.2021.540134","article-title":"Quantitative proteomic profiling identifies a potential novel chaperone marker in resistant breast cancer","volume":"11","author":"Gallegos","year":"2021","journal-title":"Front. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"B15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2164-3-18","article-title":"Expression and genomic analysis of midasin, a novel and highly conserved AAA protein distantly related to dynein","volume":"3","author":"Garbarino","year":"2002","journal-title":"BMC Genomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm1684","article-title":"AAA+ proteins: have engine, will work","volume":"6","author":"Hanson","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"857836","DOI":"10.3389\/fgene.2022.857836","article-title":"MDN1 mutation is associated with high tumor mutation burden and unfavorable prognosis in breast cancer","volume":"13","author":"Hao","year":"2022","journal-title":"Front. Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1038\/s41388-022-02483-8","article-title":"Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer","volume":"41","author":"Harrod","year":"2022","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cell.2016.08.070","article-title":"Potent, reversible, and specific chemical inhibitors of eukaryotic ribosome biogenesis","volume":"167","author":"Kawashima","year":"2016","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1158\/1538-7445.am2025-2845","article-title":"Abstract 2845: midasin overexpression drives intrinsic endocrine resistance by stabilizing DNA damage","volume":"85","author":"Kotina","year":"2025","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1038\/s41598-020-62279-2","article-title":"OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine","volume":"10","author":"L\u00f3pez-Cort\u00e9s","year":"2020","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-\u03b1: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"18459","DOI":"10.1073\/pnas.2002792117","article-title":"Long-range intramolecular allostery and regulation in the dynein-like AAA protein Mdn1","volume":"117","author":"Mickolajczyk","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1080\/07391102.2024.2305695","article-title":"Development of venetoclax with 2-hydroxypropyl-beta-cyclodextrin inclusion complex for improved bioavailability","volume":"43","author":"Patil","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/biom9110715","article-title":"Shaping the nascent ribosome: aaa-atpases in eukaryotic ribosome biogenesis","volume":"9","author":"Prattes","year":"2019","journal-title":"Biomolecules"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:42:46Z","timestamp":1784266966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1852788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1852788"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1852788","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1852788"}}